Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 52.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 30,806 shares of the company’s stock after selling 33,479 shares during the period. Jane Street Group LLC’s holdings in Tenaya Therapeutics were worth $59,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its position in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after acquiring an additional 7,000 shares in the last quarter. Algert Global LLC bought a new position in shares of Tenaya Therapeutics during the second quarter worth about $74,000. SG Americas Securities LLC acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth about $49,000. Walleye Capital LLC bought a new stake in Tenaya Therapeutics in the 3rd quarter valued at about $134,000. Finally, Rhumbline Advisers raised its holdings in shares of Tenaya Therapeutics by 10.5% during the second quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock valued at $242,000 after buying an additional 7,441 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $1.47 on Thursday. Tenaya Therapeutics, Inc. has a 1 year low of $0.99 and a 1 year high of $7.01. The stock has a market cap of $116.45 million, a PE ratio of -1.02 and a beta of 2.89. The business’s fifty day moving average is $2.28 and its 200-day moving average is $2.46.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Equities research analysts predict that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

TNYA has been the subject of a number of recent analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.